Conivaptan
Vaprisol (conivaptan) is a small molecule pharmaceutical. Conivaptan was first approved as Vaprisol on 2005-12-29. It is used to treat hyponatremia in the USA. The pharmaceutical is active against vasopressin V1a receptor and vasopressin V2 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Vaprisol
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Conivaptan hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER | Cumberland Pharmaceuticals | N-021697 RX | 2008-10-08 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vaprisol dextrose in plastic container | New Drug Application | 2016-10-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyponatremia | HP_0002902 | D007010 | E87.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| C9488 | Injection, conivaptan hydrochloride, 1 mg |
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 2 | 8 | 1 | 1 | 10 |
| Infections | D007239 | EFO_0000544 | — | — | 4 | 1 | 1 | 6 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | 1 | 2 | — | 4 |
| Acinetobacter infections | D000151 | EFO_1000792 | — | — | — | 1 | 2 | 3 | |
| Bacterial infections | D001424 | A49 | — | — | 1 | 1 | 1 | 3 | |
| Critical illness | D016638 | 1 | — | — | 1 | — | 2 | ||
| Communicable diseases | D003141 | — | — | 1 | 1 | — | 2 | ||
| Gram-negative bacterial infections | D016905 | — | — | — | 2 | — | 2 | ||
| Cross infection | D003428 | — | — | 1 | 1 | — | 2 | ||
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 1 | 2 | — | 1 | 3 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 2 | — | 1 | 3 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | 3 | ||
| Sepsis | D018805 | A41.9 | — | — | 1 | — | 1 | 2 | |
| Iatrogenic disease | D007049 | — | — | 1 | — | — | 1 | ||
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | 1 | — | — | 1 | |
| Bronchitis | D001991 | J40 | — | — | 1 | — | — | 1 | |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 1 | — | — | 1 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 1 | — | — | 1 |
| Healthcare-associated pneumonia | D000077299 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pseudomonas aeruginosa | D011550 | NCBITaxon_287 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CONIVAPTAN |
| INN | conivaptan |
| Description | Conivaptan is the amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). It has a role as a vasopressin receptor antagonist and an aquaretic. |
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror; vasopressin receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2 |
Identifiers
| PDB | — |
| CAS-ID | 210101-16-9 |
| RxCUI | 302285 |
| ChEMBL ID | CHEMBL1755 |
| ChEBI ID | 681850 |
| PubChem CID | 151171 |
| DrugBank | DB00872 |
| UNII ID | 0NJ98Y462X (ChemIDplus, GSRS) |
Target
Agency Approved
AVPR1A
AVPR1A
AVPR2
AVPR2
Organism
Homo sapiens
Gene name
AVPR1A
Gene synonyms
AVPR1
NCBI Gene ID
Protein name
vasopressin V1a receptor
Protein synonyms
Antidiuretic hormone receptor 1a, AVPR V1a, SCCL vasopressin subtype 1a receptor, V1-vascular vasopressin receptor AVPR1A, V1a vasopressin receptor, Vascular/hepatic-type arginine vasopressin receptor
Uniprot ID
Mouse ortholog
Avpr1a (54140)
vasopressin V1a receptor (Q9QYH2)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vaprisol - Cumberland Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 550 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,138 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more